1. Scrip
  2. >>New Products

Clovis’s Rubraca Is First PARP For Prostate Cancer, But AZ’s Lynparza Coming Soon

 
• By Mary Jo Laffler

The limitations of launching during the pandemic will make it difficult to capitalize on a short window between the approvals.

Being first to market has helped cement AstraZeneca PLC’s lead in the PARP inhibitor space with Lynparza (olaparib), now partnered with Merck & Co. Inc.Clovis Oncology Inc. is now first to the lucrative prostate cancer market with Rubraca (rucaparib), but Lynparza’s imminent approval and the difficulties of launching during a pandemic will make it difficult to capitalize on that advantage.

The US Food and Drug Administration granted accelerated approval for Rubraca on 15 May for treatment of adult patients with a deleterious BRCA1/BRCA2 mutation (germline and/or somatic)-associated, metastatic castration-resistant prostate cancer (mCRPC) who have

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.